Research output: Contribution to journal › Article › peer-review
Comparison of Pharmacokinetic Parameters and Biodistribution of Full-Size Antibodies and Nanoantibodies Specific to Human PD-L1. / Verlov, N.; Shashkova, O.; Krutetskaia, I.; Terekhina, L.; Shatik, S.; Pinevich, A.; Burdakov, V.; Kulakov, I.; Shtam, T.; Konevega, A.; Stanzhevskii, A.; Samoilovich, M.
In: Nanobiotechnology Reports, Vol. 19, No. Suppl 1, 2024, p. S210-S217.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Comparison of Pharmacokinetic Parameters and Biodistribution of Full-Size Antibodies and Nanoantibodies Specific to Human PD-L1
AU - Verlov, N.
AU - Shashkova, O.
AU - Krutetskaia, I.
AU - Terekhina, L.
AU - Shatik, S.
AU - Pinevich, A.
AU - Burdakov, V.
AU - Kulakov, I.
AU - Shtam, T.
AU - Konevega, A.
AU - Stanzhevskii, A.
AU - Samoilovich, M.
N1 - Export Date: 01 November 2025; Cited By: 0; Correspondence Address: N. Verlov; Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre “Kurchatov Institute, Gatchina, Russian Federation; email: verlov_na@pnpi.nrcki.ru
PY - 2024
Y1 - 2024
N2 - The study of pharmacokinetic parameters and biodistribution of radiopharmaceuticals is the most important stage in the study of their effectiveness and safety for clinical usage. In the present work, a comparative study of 125I-labeled full-size therapeutic antibodies to human PD-L1 and recombinant single-domain heavy-chain antibodies (VHH) specific to the same biomarker was conducted. A mouse model of the tumor process induced by transplantation of CT26-PD-L1 recombinant cells stably expressing human PD-L1 receptor on their surface was used. The half-life time for VHH was almost 10 times shorter than for full-size antibodies while both pharmaceuticals demonstrated the ability of specific accumulation in CT26-PD-L1 tumor. The route of excretion for both drugs was mainly through urine. An abnormally rapid decrease of VHH concentration in the blood of mice was noted at the first 5 min after the radioconjugate administration. © 2025 Elsevier B.V., All rights reserved.
AB - The study of pharmacokinetic parameters and biodistribution of radiopharmaceuticals is the most important stage in the study of their effectiveness and safety for clinical usage. In the present work, a comparative study of 125I-labeled full-size therapeutic antibodies to human PD-L1 and recombinant single-domain heavy-chain antibodies (VHH) specific to the same biomarker was conducted. A mouse model of the tumor process induced by transplantation of CT26-PD-L1 recombinant cells stably expressing human PD-L1 receptor on their surface was used. The half-life time for VHH was almost 10 times shorter than for full-size antibodies while both pharmaceuticals demonstrated the ability of specific accumulation in CT26-PD-L1 tumor. The route of excretion for both drugs was mainly through urine. An abnormally rapid decrease of VHH concentration in the blood of mice was noted at the first 5 min after the radioconjugate administration. © 2025 Elsevier B.V., All rights reserved.
KW - Controlled drug delivery
KW - Macroinvertebrates
KW - Nanoclay
KW - Pharmacokinetics
KW - Biodistributions
KW - Clinical usage
KW - Comparatives studies
KW - Half life time
KW - Heavy-chain antibodies
KW - Mice models
KW - Pharmacokinetic parameters
KW - Recombinant cells
KW - Single domains
KW - Therapeutic antibodies
KW - Mammals
U2 - 10.1134/S2635167624602742
DO - 10.1134/S2635167624602742
M3 - статья
VL - 19
SP - S210-S217
JO - Nanobiotechnology Reports
JF - Nanobiotechnology Reports
SN - 2635-1676
IS - Suppl 1
ER -
ID: 143410865